Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis.

about

Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis.

Item

http://www.wikidata.org/entity/Q49682864

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Serum interleukin-6 level is a ...... liximab in ulcerative colitis.

@en

Serum interleukin-6 level is a ...... liximab in ulcerative colitis.

@nl

type

Item

label

Serum interleukin-6 level is a ...... liximab in ulcerative colitis.

@en

Serum interleukin-6 level is a ...... liximab in ulcerative colitis.

@nl

prefLabel

Serum interleukin-6 level is a ...... liximab in ulcerative colitis.

@en

Serum interleukin-6 level is a ...... liximab in ulcerative colitis.

@nl

P1476

Serum interleukin-6 level is a ...... liximab in ulcerative colitis.

@en

P2093

Fumio Tanaka

http://www.w3.org/2001/XMLSchema#string

Hirokazu Yamagami

http://www.w3.org/2001/XMLSchema#string

Kenji Watanabe

http://www.w3.org/2001/XMLSchema#string

Kimihiko Watanabe

http://www.w3.org/2001/XMLSchema#string

Koichi Taira

http://www.w3.org/2001/XMLSchema#string

Koji Otani

http://www.w3.org/2001/XMLSchema#string

Noriko Kamata

http://www.w3.org/2001/XMLSchema#string

Shuhei Hosomi

http://www.w3.org/2001/XMLSchema#string

Tetsuya Tanigawa

http://www.w3.org/2001/XMLSchema#string

Tomomi Yukawa

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis

Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn's disease

Infliximab for induction and maintenance therapy for ulcerative colitis

Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study

Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up.

Anti-IL-13 in inflammatory bowel disease: from the bench to the bedside.

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Interrelations between interleukin-6, interleukin-1 beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease.

Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity.

Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease

P304

1-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/00365521.2017.1403647

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29171305

http://www.w3.org/2001/XMLSchema#string